This article has Open Peer Review reports available.
Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease
- Philipp Schuetz†1Email author,
- Mirjam Christ-Crain†1,
- Ursula Schild1,
- Erika Süess1,
- Michael Facompre2,
- Florent Baty2,
- Charly Nusbaumer3,
- Martin Brutsche2 and
- Beat Müller1
© Schuetz et al; licensee BioMed Central Ltd. 2008
Received: 20 August 2007
Accepted: 26 January 2008
Published: 26 January 2008
As supra-physiological intake of corticosteroids is a well known risk factor for the development of adrenal insufficiency, we investigated the function of the hypothalamic-pituitary-adrenal (HPA) axis during a 14-day course of systemic corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary disease using clinical and laboratory measures.
A systematic clinical and laboratory assessment including measurement of basal cortisol levels and the response to low dose (1 μg) ACTH stimulation was performed in nine patients before, on the first and the last day of treatment, as well as 2, 7 and 21 days after corticosteroid withdrawal.
At baseline, all nine patients had normal responses to 1 μg ACTH. On the first day of steroid treatment, 78% had a blunted peak cortisol response. This percentage increased to 89% after 14 days of steroid treatment. 78%, 33% and 33% of the patients had a blunted cortisol response to ACTH 2, 7, and 21 days after corticosteroid withdrawal, respectively. ROC curve analysis revealed that only basal cortisol concentrations (AUC 0.89), but not ACTH concentrations (AUC 0.49) or clinical signs (AUC 0.47) were predictive of an impaired function of the HPA axis. Basal cortisol levels of > 400 and < 150 nmol/l were 96% and 100% sensitive for a normal or pathological response to the ACTH stimulation test, respectively.
Immediate and prolonged suppression of the HPA axis is a common finding in otherwise asymptomatic patients undergoing systemic steroid treatment for acute exacerbation of chronic obstructive pulmonary disease and can reliably be assessed with the low-dose ACTH test.
The administration of a 2 week course of systemic corticosteroids to treat patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) has become common practice over the past 30 years . This practice, however, remains debated because corticosteroids are only modestly effective in shortening the duration of exacerbations of COPD and have serious metabolic adverse effects including hyperglycemia, osteoporosis, myopathies, mental disturbances and suppression of the hypothalamic-pituitary-adrenal (HPA) axis, among others .
Adrenal insufficiency often presents with only minimal and unspecific clinical prodromal symptoms but may suddenly become life-threatening if left untreated upon acute stress (e.g. infection, acute exacerbation, trauma or critical illness). Predicting adrenal insufficiency is challenging, since neither the dose nor the duration of glucocorticoid treatment, nor random plasma cortisol measurements correlate with the function of the HPA axis . The insulin-induced hypoglycaemia test is the most agreed-on reference standard for "stress" and for the verification of adrenal insufficiency . The insulin tolerance test, however, is labour-intensive, potentially dangerous and unpleasant for the patient, and thus, not feasible outside an endocrine unit. In clinical practice, the simpler low-dose corticotropin (ACTH) test is a useful and sensitive substitute as it reveals partial adrenal insufficiency by providing physiological adrenocortical stimulation [6, 7].
The aim of this study was to assess occurrence and time course of adrenal suppression in patients undergoing a 14 day course of systemic corticosteroids for AECOPD by means of the low-dose corticotropin test.
From October 2005 to June 2006, we prospectively included nine consecutive patients aged 40 years or older, who were admitted to the University Hospital in Basel, Switzerland, for acute exacerbation of COPD with >1 of the following symptoms: increase in dyspnea, increase in sputum, discolouration of sputum . In all patients pneumonia was excluded by chest radiograph. All patients had a standardized steroid treatment with a single injection of 40 mg of methylprednisolone (Solumedrol®), followed by an oral 13-day regime of 40 mg prednisone (Prednisone®). In addition, in all patients a medical treatment with inhaled long acting β2-agonists and inhaled corticosteroids was initiated. Patients who received systemic glucocorticoid treatment within the last 6 months and patients with known Addison's disease, adrenal metastases, Cushing's disease or pituitary adenomas were excluded from the study.
After study inclusion, all patients were examined on 5 clinical visits, namely on days 2 and 14 (the second and the last day of steroid treatment) and on days 16, 21 and 35, respectively. On every visit, the patients' functional status and a clinical questionnaire, adapted from a published clinical adrenal insufficiency score were assessed (range 0–10 for each symptom, higher scores indicate greater discomfort) . A subset of patients (n = 5) was asked at different time points to self-report their functional status with the help of a visual analogue scale, ranging from 0 (feeling extremely ill) to 100 (feeling completely healthy).
The study was approved by the institutional review board (Ethikkommission beider Basel, EKBB) and written informed consent was obtained from all included patients. All data were held and analyzed by the authors.
Prior to the initial administration of intravenous methylprednisolone and in the morning of all 5 clinical visits, low-dose (1 μg) ACTH tests were performed by a specialist study nurse. On all occasions, blood samples were taken at 0 min for the assessment of basal cortisol and basal ACTH concentrations, and again 30 min after intravenous (i.v.) administration of 1 μg corticotropin (synthetic ACTH1–24) for the measurement of stimulated serum cortisol concentrations. Based on prior studies in our Institution and the endocrine literature, a normal response to intravenous corticotropin was defined as a stimulated plasma cortisol concentration > 550 nmol/l [7, 10–13]. Blood samples were immediately centrifuged, aliquoted, and stored at -70°C until batch analyses. Serum total cortisol was measured using a chemiluminescence immunoassay (DPC® Diagnostic Products Corporation, Los Angeles, CA) with a calculated sensitivity of 13.8 nmol/l. The intra-assay coefficient of variation was 4.4%, and the inter-assay coefficient of variation was 11.0%. Serum ACTH was measured using a chemiluminescence immunoassay (DPC® Diagnostic Products Corporation) with a sensitivity of 1 ng/l.
To evaluate differences between groups, the Mann-Whitney U test and the Wilcoxon signed rank sum test for not normally distributed unpaired and paired variables, and the Fisher's exact test for categorical variables were used, as appropriate. To compare the prognostic value of individual laboratory markers for predicting HPA insufficiency as assessed by the corticotropin test, a receiver operating characteristic (ROC) analysis was performed . The area under the ROC curve (AUC) was the measure of the accuracy of the laboratory parameter to distinguish the groups. A p-value <0.05 (for a 2-sided test) was considered statistically significant. All calculations were performed using Stata 9.2 (Stata Corp, College Station, Tex).
Baseline values for all patients (n = 9)
Body-mass index (kg/m 2)*
Smoking (pack years)*
Duration of COPD (years)*
Number of AECOPD in previous year*
Duration of AECOPD (days)
Increased sputum production (%)
Discoloured sputum (%)
Maintenance therapy at admission (%)
β2-agonist and/or anticholinergic
Long-term oxygen therapy
Severity of AECOPD – Anthonisen's criteria  (%)
Heart rate* (beats/min)
Blood pressure* (mmHg)
Cortisol basal (nmol/l)**
Cortisol after 1 μg ACTH (nmol/l)**
Basal ACTH (ng/l)**
Adrenal function test
Before the initiation of steroid therapy, all patients (100%) had a normal rise of cortisol after injection of 1 μg ACTH defined as a stimulated cortisol value > 550 nmol/l [7, 11, 12]. On the first day of steroid treatment, 78% of patients had a blunted peak cortisol response. This percentage increased to 89% after 14 days of steroid treatment. 78%, 33% and 33% of the patients had a blunted cortisol response to 1 μg ACTH injection, 2, 5, and 14 days after corticosteroid withdrawal, respectively.
Median basal plasma cortisol (nmol/l) concentrations were significantly higher in patients with a normal adrenal response as compared to patients with a suppressed adrenal response (409 (95%CI 366–482) vs 142 (IQR 129–218)), p < 0.0001). Median ACTH concentrations (pmol/ml) were similar on baseline as compared to the 5 clinical visits (p > 0.05 for each measurement) and for all patients with normal and insufficient rise of cortisol after injection of 1 μg ACTH (14.4 (95%CI 11.3–21.7) vs 8.6 (95%CI 8.3–16.1), p = 0.1).
Baseline cortisol concentration, cortisol concentration after stimulation with 1 μg corticotropin and clinical data of all 9 patients and all 6 clinical visits.
Laboratory and clinical parameters
Prediction of adrenal insufficiency
Sensitivity, specificity, percentage of correctly classified patients and positive and negative likelihood ratio of basal cortisol at different cut off values
Cut-off value of basal cortisol
Patients prescribed an oral and inhaled corticosteroid are at a dose related increased risk of adrenal crisis as illustrated in a recently published epidemiological case control study of 154 reported cases in the general population . The magnitude of the risk for an individual patient with oral and inhaled corticosteroids for AECOPD, however, has not yet been determined and is often neglected in common practice . A sensitive measure to assess the functional status of the HPA-axis, and thus the risk for Addisonian crises upon stress, is the low-dose ACTH-test. In this study, even short-term low-dose courses of systemic corticosteroids for the treatment of AECOPD in steroid naive patients was associated with a measurable and prolonged suppression of the HPA-axis in the majority of patients. Importantly, clinical signs and symptoms are unreliable and unable to predict an impairment of the HPA-axis. Accordingly, in patients with AECOPD receiving systemic corticosteroids the presence of adrenal insufficiency should be considered.
Physiologically, the hypothalamus secretes corticotropin releasing hormone (CRH), which stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH leads to the release of cortisol through stimulation of the adrenal cortex, which in turn has a negative feedback on CRH and ACTH. Administration of exogenous corticosteroids, even in small doses for only few days, leads to a measurable suppression of the HPA-axis resulting in the inability of the adrenal cortex to secrete additional cortisol if needed . One might argue that laboratory changes in the HPA axis after short-term systemic steroid therapy are not of clinical relevance. Indeed, the absolute risk of adrenal crisis after cessation of oral and inhaled corticosteroids might be considered rare based on the literature, but is likely to be substantially underreported in clinical practice . Importantly, the manifestation and the severity of clinical signs depend on the presence of stress with its resulting increased cortisol demand. Upon major stress, even a mild adrenal insufficiency can be hazardous leading to hemodynamic instability, vasoactive-refractory shock and ultimatively death [3, 15, 18]. Consequently, in adrenal insufficiency administration of systemic corticosteroids (preferably hydrocortisone) is mandatory and potentially lifesaving. Unfortunately, symptoms of adrenal insufficiency are highly variable and only occur if the patient is experiencing more or less severe stress. Therefore, predicting or excluding the risk for adrenal insufficiency from clinical parameters, as often falsely done, is delicate and potentially dangerous. Illustratively, typical symptoms of adrenal insufficiency (e.g. weakness, low blood pressure and hypoglycemia) were completely nonspecific in this study and were, thus, unreliable predictors of adrenal insufficiency. This should be kept in mind before an absence of adrenal insufficiency is postulated based on the absence of signs and symptoms by the treating physician.
Based on our data and supported by the literature, basal cortisol levels are helpful to diagnose adrenal insufficiency in a subset of patients, i.e. if cortisol values are < 150 or > 400 nmol/l adrenal insufficiency is highly likely or can be excluded, respectively. Measurement of basal ACTH concentration did not improve the diagnostic accuracy. This is not surprising because of the pulsatile secretion of ACTH.
In asthmatic patients, the various adverse effects of oral and even inhaled corticosteroids on the HPA axis, including adrenal crisis, have been well recognized [18, 19]. In patients receiving systemic corticosteroids for acute exacerbation of COPD, the frequency and duration of adrenal suppression has not prospectively been investigated. Surprisingly, in common practice, a so called "short-term" 14 days course of systemic corticosteroids is generally considered safe and the potential consequences of adrenal suppression are often neglected . In our patients, adrenal stimulation tests revealed a suppressed adrenal response to corticotropin in 7 out of 9 patients after only one day of treatment and in 8 out of 9 patients after the 2 weeks course. Similar proportions have been reported from studies on longer-term glucocorticoid treatment . The observed gradual recovery of the suppressed adrenal response to the low-dose corticotropin test was heterogeneous among the patients lasting from a few days to up to 3 weeks after withdrawal. In individual patients, it is not possible to predict the duration of the HPA axis recovery, though, careful instruction and observation of these patients and examination for potential adrenal insufficiency should be recommended.
This study has limitations. Firstly, we have only included a small, but well defined number of patients to assess the adrenal response after steroid treatment for AECOPD. The number of performed tests is too small to recommend definitive cut-off levels for peak cortisol concentrations during acute illnesses. Secondly, our population varied in respect to the use of inhaled corticosteroids on admission, which is a known risk factor for adrenal insufficiency. However, all patients had a normal ACTH stimulation test at baseline and the inhaled medical treatment with inhaled long acting β2-agonists and corticosteroids after study inclusion was uniform. Still, the impact of inhaled corticosteroids can not be addressed with this study. Thirdly, we did not directly assess free cortisol values or albumin or cortisol binding globulin concentrations to calculate free cortisol levels. Depending on the severity and kinetic of acute disease, total and free cortisol levels may show discordant results and total cortisol levels may not adequately anticipate the free cortisol levels needed during severe peracute stress .
In conclusion, short-term, low-dose systemic steroid treatment for AECOPD exposes the patients to the risk of adrenal insufficiency. During the period of recovery the function of the adrenal response to stress may still be impaired. In a minority of patients the adrenal response even remained suppressed for several weeks. If patients are exposed to stress after such treatment, adrenal function should be assessed.
The authors would like to thank Fausta Chiaverio for her great contribution and support of the research team and the staff from the emergency room of the University Hospital in Basel for their support during the recruitment phase of the study.
- Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999, 340: 1941-1947. 10.1056/NEJM199906243402502.View ArticlePubMedGoogle Scholar
- Niewoehner DE: The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med. 2002, 1: 243-248.View ArticlePubMedGoogle Scholar
- Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003, 348: 727-734. 10.1056/NEJMra020529.View ArticlePubMedGoogle Scholar
- Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000, 355: 542-545. 10.1016/S0140-6736(99)06290-X.View ArticlePubMedGoogle Scholar
- Rasmuson S, Olsson T, Hagg E: A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf). 1996, 44: 151-156. 10.1046/j.1365-2265.1996.600482.x.View ArticleGoogle Scholar
- Thaler LM, Blevins LS: The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab. 1998, 83: 2726-2729. 10.1210/jc.83.8.2726.PubMedGoogle Scholar
- Abdu TA, Elhadd TA, Neary R, Clayton RN: Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab. 1999, 84: 838-843. 10.1210/jc.84.3.838.PubMedGoogle Scholar
- Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987, 106: 196-204.View ArticlePubMedGoogle Scholar
- Arlt W, Rosenthal C, Hahner S, Allolio B: Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf). 2006, 64: 384-389.Google Scholar
- Widmer IE, Puder JJ, Konig C, Pargger H, Zerkowski HR, Girard J, Muller B: Cortisol response in relation to the severity of stress and illness. J Clin Endocrinol Metab. 2005, 90: 4579-4586. 10.1210/jc.2005-0354.View ArticlePubMedGoogle Scholar
- Dickstein G, Shechner C, Nicholson WE, Rosner I, Shen-Orr Z, Adawi F, Lahav M: Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991, 72: 773-778.View ArticlePubMedGoogle Scholar
- Clayton RN: Short Synacthen test versus insulin stress test for assessment of the hypothalamo [correction of hypothalmo]-pituitary – adrenal axis: controversy revisited. Clin Endocrinol (Oxf). 1996, 44: 147-149. 10.1046/j.1365-2265.1996.666478.x.View ArticleGoogle Scholar
- Berneis K, Staub JJ, Gessler A, Meier C, Girard J, Muller B: Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab. 2002, 87: 5470-5475. 10.1210/jc.2001-011959.View ArticlePubMedGoogle Scholar
- DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.View ArticlePubMedGoogle Scholar
- Mortimer KJ, Tata LJ, Smith CJ, West J, Harrison TW, Tattersfield AE, Hubbard RB: Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax. 2006, 61: 405-408. 10.1136/thx.2005.052456.View ArticlePubMedPubMed CentralGoogle Scholar
- Vondracek SF, Hemstreet BA: Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease?. Pharmacotherapy. 2006, 26: 522-532. 10.1592/phco.26.4.522.View ArticlePubMedGoogle Scholar
- Krasner AS: Glucocorticoid-induced adrenal insufficiency. Jama. 1999, 282: 671-676. 10.1001/jama.282.7.671.View ArticlePubMedGoogle Scholar
- Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D: Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002, 87: 457-461. 10.1136/adc.87.6.457.View ArticlePubMedPubMed CentralGoogle Scholar
- Lipworth BJ: The ISOLDE trial. Side effects with inhaled steroids should not be forgotten. Bmj. 2000, 321: 1349-10.1136/bmj.321.7272.1349.View ArticlePubMedPubMed CentralGoogle Scholar
- Schlaghecke R, Kornely E, Santen RT, Ridderskamp P: The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992, 326: 226-230.View ArticlePubMedGoogle Scholar
- Christ-Crain M, Jutla S, Widmer I, Couppis O, Konig C, Pargger H, Puder J, Edwards R, Muller B, Grossman AB: Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation. J Clin Endocrinol Metab. 2007, 92: 1729-1735. 10.1210/jc.2006-2361.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/8/1/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.